- Home
- EDRY vs ESLA Comparison
EDRY vs ESLA Comparison
Compare EDRY & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- ESLA
- Stock Information
- Founded
- EDRY 2018
- ESLA 2021
- Country
- EDRY Greece
- ESLA United States
- Employees
- EDRY N/A
- ESLA N/A
- Industry
- EDRY Marine Transportation
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDRY Consumer Discretionary
- ESLA Health Care
- Exchange
- EDRY Nasdaq
- ESLA Nasdaq
- Market Cap
- EDRY 25.2M
- ESLA 35.5M
- IPO Year
- EDRY N/A
- ESLA N/A
- Fundamental
- Price
- EDRY $9.67
- ESLA $0.91
- Analyst Decision
- EDRY
- ESLA Strong Buy
- Analyst Count
- EDRY 0
- ESLA 1
- Target Price
- EDRY N/A
- ESLA $16.00
- AVG Volume (30 Days)
- EDRY 7.7K
- ESLA 521.7K
- Earning Date
- EDRY 06-05-2025
- ESLA 08-20-2025
- Dividend Yield
- EDRY N/A
- ESLA N/A
- EPS Growth
- EDRY N/A
- ESLA N/A
- EPS
- EDRY N/A
- ESLA N/A
- Revenue
- EDRY $55,867,583.00
- ESLA N/A
- Revenue This Year
- EDRY N/A
- ESLA $101.09
- Revenue Next Year
- EDRY $28.27
- ESLA N/A
- P/E Ratio
- EDRY N/A
- ESLA N/A
- Revenue Growth
- EDRY 10.25
- ESLA N/A
- 52 Week Low
- EDRY $7.60
- ESLA $0.63
- 52 Week High
- EDRY $24.79
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- EDRY 61.17
- ESLA 49.49
- Support Level
- EDRY $8.95
- ESLA $0.89
- Resistance Level
- EDRY $11.85
- ESLA $1.02
- Average True Range (ATR)
- EDRY 0.55
- ESLA 0.08
- MACD
- EDRY 0.09
- ESLA -0.00
- Stochastic Oscillator
- EDRY 35.11
- ESLA 45.00
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.